Investigational drugs targeting FLT3 for leukemia (Q37577934)

21 August 2017

1 reference

title

Investigational drugs targeting FLT3 for leukemia (English)

1 reference

21 August 2017

1 reference

Celalettin Ustun

1

1 reference

21 August 2017

David L DeRemer

series ordinal

2

1 reference

21 August 2017

Anand P Jillella

series ordinal

3

1 reference

21 August 2017

Kapil N Bhalla

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

18

1 reference

21 August 2017

10

1 reference

21 August 2017

1445-1456

1 reference

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

FLT3 mutations in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Structural and numerical variation of FLT3/ITD in pediatric AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Clinical implications of FLT3 mutations in pediatric AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Antitumor activity of sorafenib in FLT3-driven leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903179278

10.1517/13543780903179278

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference